gabapentin recall granules gabapentin renal impairment

Drug Recall Enforcement Report Class II voluntary initiated by Granules Pharmaceuticals Inc., initiated on 07-31-2024 for the product Gabapentin Tablets, USP, FDA Announces Voluntarily Recall for Batch of Gabapentin 300 MG Capsules Epilepsy News From: Tuesday, November 25, 2014 The U.S. Food and Drug Administration (FDA) has reported that Aurobindo Pharma USA is voluntarily recalling Gabapentin 300 mg capsules from lot GESB14011-A in 100-count bottles. The last Recall Enforcement Report for Gabapentin with NDC 70010-227 was initiated on 07-31-2024 as a Class II recall and it is currently ongoing. Granules Pharmaceuticals, Inc., Chantilly, VA is voluntarily recalling twelve (12) lots of Metformin Hydrochloride Extended-Release Tablets USP, 750 mg, 100 and 500 count bottles within expiry to On December 19, 2019 FDA is warning that serious breathing difficulties may occur in patients using gabapentin (brand names Neurontin, Gralise, Horizant) or pregabalin (brand names Lyrica, Gabapentin Tablets, USP, 600 mg, 500-count bottles, Rx only, Manufactured by: Granules India Limited Hyderabad-500 081, India, Manufactured for: Granules Pharmaceuticals Inc., Chantilly, VA NDC 70010-227-05: Reason For Recall The last Recall Enforcement Report for Gabapentin with NDC 50228-178 was initiated on 02-17-2023 as a Class III recall due to presence of foreign tablets/capsules: pharmacist reported presence of some gabapentin tablets 800 mg comingled in gabapentin 600 mg 500 count bottles. Mandated? Product mixup: one foreign tablet found in product. On July 31, 2024, Granules Pharmaceuticals Inc. recalled one lot of gabapentin 600mg tablets. The recall was initiated due to an error resulting in metformin extended-release tablets found in a bottle of gabapentin 600mg tablets. Nerve Pain, Seizure Drug Recalled. The Harvard Drug Group is pulling 3984 cartons of gabapentin tablets after a foreign tablet was found in a carton, according to the May 17, 2023, US Food and Drug Administration (FDA) Enforcement Report. Aurobindo Pharma USA has initiated a voluntary recall of one lot of 300-mg capsules of the antiepileptic agent gabapentin because some of the capsules have been found to be empty, the company Get an alert when a recall is issued. Do not use • if you are now taking a prescription monoamine oxidase inhibitor (MAOI) (certain drugs for depression, psychiatric or emotional conditions, or Parkinson’s disease), or for 2 weeks after stopping the MAOI drug. Drug Recall Enforcement Report Class III voluntary initiated by The Harvard Drug Group, originally initiated on 04-24-2023 for the product Gabapentin Tablets, USP 600 mg, packaged in Cartons of 100 tablets (10 tablets per blister pack x 10), Rx Only, Distributed by: Aurobindo Pharma USA, Inc. East Windsor, NJ 08520 Distributed by: Major Pharmaceuticals 17177 N Laurel Park Dr., Suite 233 (manufactured by Granules Pharmaceuticals) On 7/22/2020, Granules Pharmaceuticals recalled Metformin ER due to the presence of an impurity. The U.S. Food and Drug Administration (FDA) has issued a Class II recall of the affected medications. GRANULES PHARMACEUTICALS INC. is recalling Gabapentin Tablets USP, 600mg. This recall is due to a potential mix-up of Metformin ER Tablets in a bottle of Gabapentin Tablets, USP 600mg. The ongoing investigation revealed that the issue is limited to the above lot and no other lots were impacted. This recall has been initiated due to a product complaint where one incorrect tablet, identified as Atorvastatin Calcium Tablets, 40 mg, was found in blister packaging for Gabapentin Tablets, USP, 600 mg. product name dosage form rx/otc brand reference image ndc number dailymed link Drug Recall Enforcement Report Class III voluntary initiated by Sciegen Pharmaceuticals Inc, originally initiated on 02-17-2023 for the product Gabapentin Tablets, USP 600 mg, 500 tablets per bottle, RX Only, Manufactured by ScieGen Pharmaceuticals Inc., Hauppauge, NY 11788, NDC: 50228-177-05. Granules Pharmaceuticals, Inc. issues Voluntary Nationwide Recall of Metformin Hydrochloride Extended-Release Tablets USP, 750 mg Details Release of Pledge on Company’s Shares The recall includes 7,317 devices distributed from May 11, 2018, to Sept. 5, 2019. A class I recall of the Medfusion 4000 Syringe Pump with Firmware Version 1.7.0 by Smiths Medical due to the potential for low-battery alarms to stop working.

gabapentin recall granules gabapentin renal impairment
Rating 5 stars - 1471 reviews




Blog

Articles and news, personal stories, interviews with experts.

Video